Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial

BACKGROUND: The SAVE-MORE trial demonstrated that anakinra treatment in COVID-19 pneumonia with plasma soluble urokinase plasminogen activator (suPAR) levels of 6 ng/mL or more was associated with 0.36 odds for a worse outcome compared to placebo when expressed by the WHO-Clinical Progression Scale...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinosoglou, Karolina, Kotsaki, Antigone, Gounaridi, Ioanna-Maria, Christaki, Eirini, Metallidis, Simeon, Adamis, Georgios, Fragkou, Archontoula, Fantoni, Massimo, Rapti, Aggeliki, Kalomenidis, Ioannis, Chrysos, Georgios, Boni, Gloria, Kainis, Ilias, Alexiou, Zoi, Castelli, Francesco, Serino, Francesco Saverio, Bakakos, Petros, Nicastri, Emanuele, Tzavara, Vassiliki, Safarika, Asimina, Ioannou, Sofia, Dagna, Lorenzo, Dimakou, Katerina, Tzatzagou, Glykeria, Chini, Maria, Bassetti, Matteo, Kotsis, Vasileios, Angheben, Andrea, Tsoukalas, George, Selmi, Carlo, Spiropoulou, Olga-Maria, Samarkos, Michael, Doumas, Michael, Damoraki, Georgia, Masgala, Aikaterini, Papanikolaou, Ilias, Argyraki, Aikaterini, Negri, Marcantonio, Leventogiannis, Konstantinos, Sympardi, Styliani, Gatselis, Nikolaos K., Petrakis, Vasileios, Netea, Mihai G., Panagopoulos, Periklis, Sakka, Vissaria, Milionis, Haralampos, Dalekos, George N., Giamarellos-Bourboulis, Evangelos J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791950/
https://www.ncbi.nlm.nih.gov/pubmed/36590789
http://dx.doi.org/10.1016/j.eclinm.2022.101785

Ejemplares similares

Ejemplares similares